Neuroblastomas are tumours of sympathetic origin, with a heterogeneous clinical course
ranging from localized or spontaneously regressing to widely metastatic disease …

Introduction: Children with neuroblastoma have widely divergent outcomes, ranging from
cure in> 90% of patients with low risk disease to< 50% for those with high risk disease …

Approximately half of the patients diagnosed with neuroblastoma are classified as having
high-risk disease. This group continues to have inadequate cure rates despite multiagent …

For many tumours there is a lack of randomised data from which we can guide systemic
treatments. Although gene expression profiling along with proteomics has led to advances in …

Neuroblastoma is the most common solid tumor in children under the age of one. It displays
remarkable phenotypic heterogeneity, resulting in differences in outcomes that correlate with …

Background The incidence of second malignant neoplasm (SMN) within the first ten years of
diagnosis in high-risk neuroblastoma patients treated with modern, intensive therapy is …

Histone deacetylases (HDACs) are important modulators of epigenetic gene regulation and
additionally control the activity of non-histone protein substrates. While for HDACs 1–3 and 6 …

Background Predictive preclinical models play an important role in the assessment of new
treatment strategies and as avatar models for personalised medicine; however, reliable and …

PCLAF (PCNA clamp-associated factor), also known as PAF15/KIAA0101, is overexpressed
in most human cancers and is a predominant regulator of tumor progression. However, its …

Over the past two decades, marked progress has been made in understanding the biology
of neuroblastoma; this has led to refined risk stratification and treatment modifications with …